{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:20:05Z","timestamp":1787062805842,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Many factors affect the survival rate after kidney transplantation, including laboratory tests, medicine therapy and pharmacogenomics. Tacrolimus, mycophenolate mofetil and methylprednisolone were used as an immunosuppressive regimen after kidney transplantation. The primary goal of this study was to investigate the factors affecting the tacrolimus concentrations and mycophenolate mofetil area under the curve of mycophenolic acid AUC-MPA. Secondary goals were to study the association between perioperative period laboratory tests, medicine therapy, CYP3A5 genetic polymorphisms, and survival rate in kidney renal transplant patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 303 patients aged above 18 years were enrolled in this study. Their clinical characteristics, laboratory tests, and medicine therapy regimens were collected. We followed the patients for survival for 1 year after kidney transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Multivariable logistic analyses reveal that age greater than 50 years, and the CY3A5 *3*3 genotype were independently, positively, and significantly related to tacrolimus C\/D ratio at 7 days. At 1 month of follow-up, only CYP3A5 *3*3 was associated with tacrolimus C\/D ratio. Basiliximab, Imipenem and cilastatin sodium, sex were associated with mycophenolate mofetil AUC-MPA at 7 days. In the COX regression analysis, a high-density lipoprotein cholesterol level\u22651\u2005mmol\/L was identified as a positive independent risk factors for the survival rate, while a creatinine level \u2265200 \u03bcmol\/L was a negatively independent risk factors for survival rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results suggest that age, genes, and drug-drug interaction can affect the concentration of tacrolimus.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000514","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T15:00:07Z","timestamp":1698764407000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation"],"prefix":"10.1097","volume":"34","author":[{"given":"Haolin","family":"Teng","sequence":"first","affiliation":[{"name":"Department of Urology, The First Hospital of Jilin University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Hu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Organ Regeneration & Transplantation of the Ministry of Education, Genetic Diagnosis Center, The First Hospital of Jilin University, Changchun, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Hospital of Jilin University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"R1-20250808","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.mcna.2005.05.002","article-title":"Health disparities in transplantation: focus on the complexity and challenge of renal transplantation in African Americans.","volume":"89","author":"Young","year":"2005","journal-title":"Med Clin North Am"},{"key":"R2-20250808","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","article-title":"Mechanisms of clinically relevant drug interactions associated with tacrolimus.","volume":"41","author":"Christians","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R3-20250808","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 Genotype and Tacrolimus Dosing.","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R4-20250808","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.","volume":"78","author":"St\u00f8rset","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R5-20250808","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1517\/14622416.6.4.357","article-title":"Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.","volume":"6","author":"Lee","year":"2005","journal-title":"Pharmacogenomics"},{"key":"R6-20250808","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.transproceed.2005.01.077","article-title":"Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus.","volume":"37","author":"Zhao","year":"2005","journal-title":"Transplant Proc"},{"key":"R7-20250808","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R8-20250808","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism.","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R9-20250808","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/aps.2012.136","article-title":"Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine a in early post-renal transplant recipients in China.","volume":"33","author":"Meng","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"R10-20250808","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/cts.13571","article-title":"Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.","volume":"16","author":"Alghamdi","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R11-20250808","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.","volume":"31","author":"Press","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R12-20250808","doi-asserted-by":"crossref","first-page":"3129389","DOI":"10.1155\/2022\/3129389","article-title":"Tacrolimus concentration is effectively predicted using combined clinical and genetic factors in the perioperative period of kidney transplantation and associated with acute rejection.","volume":"2022","author":"Cheng","year":"2022","journal-title":"J Immunol Res"},{"key":"R13-20250808","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action.","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"R14-20250808","first-page":"315","article-title":"Lipoprotein abnormalities in chronic kidney disease and renal transplantation.","volume":"11","author":"Barbagallo","year":"2021","journal-title":"Life (Basel)"},{"key":"R15-20250808","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41581-021-00423-5","article-title":"Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.","volume":"17","author":"Noels","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"R16-20250808","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3390\/toxins14060412","article-title":"Lipid profile is negatively associated with uremic toxins in patients with kidney failure-a tri-national cohort.","volume":"14","author":"Hobson","year":"2022","journal-title":"Toxins (Basel)"},{"key":"R17-20250808","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5414\/CN109484","article-title":"Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: a single-center experience clinical nephrology.","volume":"91","author":"Aziz","year":"2019","journal-title":"Clin Nephrol"},{"key":"R18-20250808","first-page":"23","article-title":"CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment Pharmacogenomics and personalized medicine.","volume":"11","author":"Chen","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"key":"R19-20250808","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/jcph.1428","article-title":"Influence of calcineurin inhibitor and sex on mycophenolic acid pharmacokinetics and adverse effects post-renal transplant.","volume":"59","author":"Meaney","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R20-20250808","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/TP.0b013e318188ae18","article-title":"Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication.","volume":"86","author":"H\u00f6cker","year":"2008","journal-title":"Transplantation"},{"key":"R21-20250808","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.healun.2011.08.001","article-title":"Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.","volume":"30","author":"Gijsen","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"R22-20250808","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cts.13495","article-title":"Age associations with tacrolimus and mycophenolic acid pharmacokinetics in stable Black and White kidney transplant recipients: Implications for health inequities.","volume":"16","author":"Tornatore","year":"2023","journal-title":"Clin Transl Sci"},{"key":"R23-20250808","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1600-6143.2011.03974.x","article-title":"The Impact of Medicare\u2019s lifetime immunosuppression coverage on racial disparities in kidney graft survival.","volume":"12","author":"Page","year":"2012","journal-title":"Am J Transplant"},{"key":"R24-20250808","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40266-021-00842-w","article-title":"Clinical experience with extended-release tacrolimus in older adult kidney transplant recipients: a retrospective cohort study.","volume":"38","author":"January","year":"2021","journal-title":"Drugs Aging"},{"key":"R25-20250808","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3892\/etm.2016.3523","article-title":"Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy.","volume":"12","author":"Wan","year":"2016","journal-title":"Exp Ther Med"},{"key":"R26-20250808","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.transproceed.2016.02.034","article-title":"Effect of immunosuppressive therapy on cardiovascular risk factor prevalence in kidney-transplanted children: comparative study.","volume":"48","author":"Garc\u00eda-Bello","year":"2016","journal-title":"Transplant Proc"},{"key":"R27-20250808","doi-asserted-by":"crossref","first-page":"110989","DOI":"10.1016\/j.intimp.2023.110989","article-title":"Leptin receptor gene polymorphisms in kidney transplant patients with post-transplant diabetes mellitus treated with tacrolimus.","volume":"124","author":"Dziedziejko","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"R28-20250808","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1111\/ajt.13788","article-title":"Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype.","volume":"16","author":"Pallet","year":"2016","journal-title":"Am J Transplant"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T12:01:32Z","timestamp":1754654492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000514","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,4]]}}}